The American Journal of Medicine
Volume 122, Issue 5, Supplement , Pages S3-S9 , May 2009

Defining the Problem of Treating the Patient with Hypertension and Arthritis Pain

  • William B. White, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to William B. White, MD, Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, Connecticut 06030-3940

References 

  1. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care. 2002;8(suppl):S383–S391
  2. Caporali R, Cimmino MA, Sarzi-Puttini P, et al. Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. Semin Arthritis Rheum. 2005;35(suppl 1):31–37
  3. White WB. Hypertension associated with therapies to treat arthritis and pain. Hypertension. 2004;44:123–124
  4. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477–484
  5. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? (A meta-analysis). Ann Intern Med. 1994;121:289–300
  6. Grover SA, Coupal L, Zowall H. Treating osteoarthritis with cyclooxygenase-2 specific inhibitors: what are the benefits of avoiding blood pressure destabilization?. Hypertension. 2005;45:92–97
  7. White WB. Benefits of antihypertensive therapy in older patients with hypertension. Arch Intern Med. 2000;160:149–150
  8. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;19:363:2022-2031.
  9. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2−selective inhibition. Am J Med. 1999;107:65S–70S
  10. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465–1470
  11. Whelton A, White WB, Bello AE, Puma JA, Fort JG SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959–963
  12. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens. 2000;13:1161–1167
  13. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140–145
  14. Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002;110:61–69
  15. Hermann M, Camici G, Fratton A, et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation. 2003;108:2308–2311
  16. Hermann H, Shaw S, Kiss E, et al. Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension. 2005;45:193–197
  17. White WB, Kent J, Taylor A, Verburg KM, Lefkewith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39:929–934
  18. Izhar M, Alausa T, Folker A, Hunz GE, Bakris GL. Effects of COX-inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics. Hypertension. 2004;43:574–577
  19. Klassen DK, Jane LH, Young DY, Peterson CA. Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens. 1995;8:146–153
  20. Sowers JR, White WB, Pitt B, et al. Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes. Arch Intern Med. 2005;165:161–168
  21. Mamdani M, Juurlink DN, Lee DS, et al. Cyclooxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 363:1751-1756.
  22. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study (A randomized controlled trial). JAMA. 2000;284:1247–1255
  23. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–1528
  24. White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99:91–98
  25. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy (I. Prevention of death, myocardial infarction, and stroke). BMJ. 1994;308:81–106
  26. Solomon SD, Wittes J, Finn PV, et al. Cross Trial Safety Assessment Group Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117:2104–2113
  27. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364:675–684
  28. Cannon CP, Curtis SP, FitzGerald GF, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison in 34,701 patients. Lancet. 2006;368:1771–1781
  29. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenases: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA. 2006;296:1633–1644
  30. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113:1578–1587

 As of time of publication, rofecoxib has been removed from the market by the manufacturer, etoricoxib is not FDA approved, and an FDA panel has determined lumiracoxib to be uncertain for approval.

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(09)00206-X

doi: 10.1016/j.amjmed.2009.03.002

The American Journal of Medicine
Volume 122, Issue 5, Supplement , Pages S3-S9 , May 2009

Article Tools

* Image Usage & Resolution